SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (258)11/1/2001 12:51:46 PM
From: Jim Oravetz  Read Replies (1) of 370
 
Vion Pharma 3Q Loss 13c/Shr
Dow Jones Newswires

Vion Pharmaceuticals Inc. - New Haven, Conn.
3rd Quar Sept. 30:
2001 2000
Revenue $222,000 $368,000
Net income (3,695,000) (3,246,000)
Avg shrs (basic) 27,593,000 25,805,000
Shr earns (basic)
Net income (.13) (.13)
9 Months:
Revenue 547,000 787,000
Net income (10,654,000) (9,133,000)
Avg shrs (basic) 26,658,000 23,455,000
Shr earns (basic)
Net income (.40) (.42)
Figures in parentheses are losses.

Vion Pharmaceuticals Inc. (VION) makes products and technologies to treat cancer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext